Combination of Imipenem/Cilastatin and XNW4107

DRUG2 trials

Sponsors

Evopoint Biosciences Inc.

Conditions

Complicated Urinary Tract Infection Including Acute PyelonephritisHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Phase 3

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

CompletedNCT05204563

Evopoint Biosciences Inc.Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Start: 2022-07-31End: 2024-09-29Updated: 2025-11-06

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Evopoint Biosciences Inc.Complicated Urinary Tract Infection Including Acute Pyelonephritis

Start: 2023-03-30End: 2025-12-31Target: 780Updated: 2023-02-16